Edition:
United States

Trovagene Inc (TROV.OQ)

TROV.OQ on NASDAQ Stock Exchange Capital Market

0.25USD
15 Dec 2017
Change (% chg)

$-0.18 (-41.31%)
Prev Close
$0.43
Open
$0.25
Day's High
$0.26
Day's Low
$0.24
Volume
3,154,426
Avg. Vol
131,652
52-wk High
$2.80
52-wk Low
$0.24

Latest Key Developments (Source: Significant Developments)

Trovagene Submits Protocol To FDA For Phase 2 Clinical Trial Of Pcm-075 In Combination With Zytiga®
Thursday, 14 Dec 2017 08:00am EST 

Dec 14 (Reuters) - Trovagene Inc ::TROVAGENE SUBMITS PROTOCOL TO FDA FOR PHASE 2 CLINICAL TRIAL OF PCM-075 IN COMBINATION WITH ZYTIGA® FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER.TROVAGENE INC - ‍LOOKING FORWARD TO A DECISION FROM FDA PERMITTING STUDY TO PROCEED, INITIATING MCRPC CLINICAL TRIAL IN PROSTATE CANCER IN 2018​.  Full Article

Trovagene Inc updates on clinical trial for PCM-075
Monday, 13 Nov 2017 08:00am EST 

Nov 13 (Reuters) - Trovagene Inc ::Trovagene announces activation of first clinical trial site in phase 1B/2 acute myeloid leukemia (AML) trial for PCM-075.Trovagene Inc - ‍activation of its clinical trial site for its phase 1B/2 multicenter trial of PCM-075 in patients with AML​.Trovagene Inc - ‍trial will enroll subjects in phase 1B who have relapsed or have resistant disease to no more than three prior regimens​.  Full Article

TROVAGENE REPORTS Q3 LOSS PER SHARE $0.12
Thursday, 9 Nov 2017 10:18am EST 

Nov 9 (Reuters) - Trovagene Inc ::Q3 LOSS PER SHARE $0.12.‍AS OF SEPTEMBER 30, 2017, TROVAGENE HAD APPROXIMATELY $7.4 MILLION OF CASH AND CASH EQUIVALENTS​.  Full Article

Trovagene files for offering of up to $17.5 mln- SEC filing
Wednesday, 25 Oct 2017 05:01pm EDT 

Oct 25 (Reuters) - Trovagene Inc : :Trovagene Inc files for offering of up to $17.5 million - SEC filing.  Full Article

Fda grants orphan drug designation to Trovagene's PLK1 inhibitor, PCM-075
Monday, 9 Oct 2017 08:00am EDT 

Oct 9 (Reuters) - Trovagene Inc :Fda grants orphan drug designation to trovagene's PLK1 inhibitor, PCM-075, for the treatment of acute myeloid leukemia (AML).Trovagene - initiating Phase 1b/2 open-label trial to evaluate safety & anti-leukemic activity of PCM-075 in combination with standard-of-care in patients with AML​.  Full Article

Trovagene files for offering of upto sale 4.64 mln shares of common stock by the selling stockholders‍​
Friday, 29 Sep 2017 05:32pm EDT 

Sept 29 (Reuters) - Trovagene Inc :Trovagene Inc files for offering of up to sale 4.64 million shares of common stock by the selling stockholders‍​ - SEC Filing.  Full Article

Trovagene reports positive data from a preclinical in-vivo study examining combination of their plk1 inhibitor with investigational flt3 inhibitor
Wednesday, 16 Aug 2017 08:00am EDT 

Aug 16 (Reuters) - Trovagene Inc ::Trovagene's plk1 inhibitor pcm-075, in preclinical aml data, significantly enhances the efficacy of a flt3 inhibitor in combination therapy.Trovagene Inc - positive data from a preclinical in-vivo study examining combination of their plk1 inhibitor, pcm-075, with investigational flt3 inhibitor.  Full Article

Trovagene Q2 loss per share $0.26
Wednesday, 9 Aug 2017 04:27pm EDT 

Aug 9 (Reuters) - Trovagene Inc ::Trovagene announces second quarter 2017 company highlights and financial results.Q2 loss per share $0.26.  Full Article

Trovagene, Antonius Schuh and Stephen Zaniboni resolve employment dispute
Friday, 28 Jul 2017 05:36pm EDT 

July 28 (Reuters) - Trovagene Inc :Trovagene, Antonius Schuh and Stephen Zaniboni resolve employment dispute.Trovagene Inc - Co,‍ Antonius Schuh, Stephen Zaniboni, co's former CEO,former CFO, resolved their respective legal claims against each other​.  Full Article

Trovagene announces peer-reviewed publication of first-in-human phase 1 trial results with PCM-075
Tuesday, 25 Jul 2017 08:00am EDT 

July 25 (Reuters) - Trovagene Inc :Trovagene announces peer-reviewed publication of first-in-human phase 1 trial results with pcm-075, its polo-like kinase 1 (plk1) inhibitor.Trovagene inc says data from first-in-human trial demonstrated that pcm-075 is generally safe and well-tolerated in patients with advanced cancers.  Full Article

BRIEF-Trovagene Prices $4.5 Million Public Offering

* PRICING OF PUBLIC OFFERING OF 15 MILLION SHARES OF ITS COMMON STOCK, COMMON WARRANTS TO PURCHASE UP TO 15 MILLION SHARES OF COMMON STOCK